Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chromosome 4 open reading frame 36 (C4orf36)
- Target
- C4orf36
- Molecular classification
- Other (no clear family; predicted as a divalent cation tolerance protein, "CutA" motif present but not fully characterized), Protein coding gene
01
Overview
Chromosome 4 open reading frame 36 encodes a small (~117 amino acids, ~13.3 kDa), likely cytosolic protein with a divalent cation tolerance motif ("CutA motif") and no transmembrane domains or signal peptides[1]. It shows enriched expression in placenta, thyroid, ovary, skin, kidney tubules, glomeruli, and several regions of the brain[1][8]. The precise molecular function is not fully established, but it may participate in regulation of class III PI3K complexes, intracellular transport, and stress response[1][2]. C4orf36 is highly evolutionarily conserved in mammals and turtles[1]. Increased expression is associated with chemoresistance in ovarian cancer and higher levels in pancreatic cancer patient saliva, suggesting possible relevance to disease but no known drug interactions or direct therapeutic targeting[1].
- Other names
- C4orf36Chromosome 4 open reading frame 36MGC26744LOC132989spostobufersnybyforsnyby
02
Mechanism of action
Not established. No mechanism of action reported for drugs acting on C4orf36.
03
Biological functions
Possible regulation of class III phosphatidylinositol 3-kinase complexesCoupled to oscillatory expression during chondrogenesis/embryonic skeletal developmentPossible role in intracellular cargo transport, similar to fungal dynein light chain analogMay regulate cellular stress response and age-related disordersNot definitively assigned to signal transduction, cell cycle, etc.
04
Disease associations
Cancer: High expression linked to chemoresistance in ovarian cancer cell lines to gemcitabine and decreased cancer patient survivalCancer: Higher expression in pancreatic cancer patient salivaAge-related disorders: Deregulation observed in neuroglia after exposure to adaptogenic plants
05
Safety considerations
None reported; no evidence regarding toxicity or specific safety concerns in a therapeutic context
06
Biomarkers
Upregulated in saliva of pancreatic cancer patients (potential biomarker role suggested)High expression may indicate chemoresistance in ovarian cancer lines
Beyond the preview
Go deeper on Chromosome 4 open reading frame 36 (C4orf36).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chromosome 4 open reading frame 36 (C4orf36).